Abstract
Background: Serum uric acid (SUA) is a well-known predictor of adverse outcomes in patients with various clinical conditions. However, the impact of SUA on patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) remains unclear. Here, we aimed at investigating the potential association between hyperuricemia and the adverse outcomes in MINOCA patients.Methods: Overall, 249 MINOCA patients were enrolled in the present study. Clinical characteristics and laboratory data, were measured in all patients. Based on SUA levels, patients were classified into two groups; the hyperuricemia group [SUA level > 6 mg/dL (360 μmol/L) in women and > 7 mg/dL (420 μmol/L) in men], and the normuricemia group. The primary endpoint of our study was major adverse cardiac events (MACE), defined as cardiovascular death, stroke, heart failure, non-fatal MI, and angina rehospitalization.Results: Seventy-two patients were in hyperuricemia group and 177 in normuricemia group. Fifty-two MACE events were recorded after 30 months of follow-up period. The incidence of MACE was higher in hyperuricemia group compared with normuricemia group (31.9 vs. 16.3%, P = 0.006). Kaplan-Meier survival curves illustrated a significantly increased risk of MACE in hyperuricemia group (log-rank P = 0.006). The multivariable logistic analysis demonstrated that hyperuricemia was independently associated with a high risk of MACE after 30 months of follow-up (OR, 2.234; 95% CI, 1.054–4.737, P = 0.036).Conclusion: Hyperuricemia is associated with adverse outcomes and appears to be an independent predictor of MACE in MINOCA patients. This finding suggests that the SUA levels may serve as a surrogate biomarker related to risk prediction and adverse outcomes of MINOCA patients.
Highlights
Despite great advances in our undertanding of cardiovascular diseases, myocardial infarction with non-obstructive coronary arteries (MINOCA) remains an intriguing clinical entity which has gained increased attention over the recent years, comprises 5–15% of overall acute myocardial infarction (AMI) cases [1, 2]
The present study evaluated whether hyperuricemia was associated with adverse outcomes in patients with MINOCA
Our study found that hyperuricemia is associated with adverse outcomes and appears to be an independent predictor of major adverse cardiac event (MACE) in MINOCA patients, which suggests that quantification of Serum uric acid (SUA) is an appropriate measure of predicting adverse outcomes following MINOCA
Summary
Despite great advances in our undertanding of cardiovascular diseases, myocardial infarction with non-obstructive coronary arteries (MINOCA) remains an intriguing clinical entity which has gained increased attention over the recent years, comprises 5–15% of overall acute myocardial infarction (AMI) cases [1, 2]. Elevated SUA is considered to have a potential relationship with multiple clinical conditions [8] cardiovascular diseases [9, 10]. Serum uric acid (SUA) is a well-known predictor of adverse outcomes in patients with various clinical conditions. The impact of SUA on patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) remains unclear. We aimed at investigating the potential association between hyperuricemia and the adverse outcomes in MINOCA patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
